JP2022525476A5 - - Google Patents

Info

Publication number
JP2022525476A5
JP2022525476A5 JP2021556462A JP2021556462A JP2022525476A5 JP 2022525476 A5 JP2022525476 A5 JP 2022525476A5 JP 2021556462 A JP2021556462 A JP 2021556462A JP 2021556462 A JP2021556462 A JP 2021556462A JP 2022525476 A5 JP2022525476 A5 JP 2022525476A5
Authority
JP
Japan
Application number
JP2021556462A
Other languages
Japanese (ja)
Other versions
JP2022525476A (ja
JPWO2020190990A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023250 external-priority patent/WO2020190990A1/en
Publication of JP2022525476A publication Critical patent/JP2022525476A/ja
Publication of JPWO2020190990A5 publication Critical patent/JPWO2020190990A5/ja
Publication of JP2022525476A5 publication Critical patent/JP2022525476A5/ja
Pending legal-status Critical Current

Links

JP2021556462A 2019-03-18 2020-03-18 腫瘍選択的併用療法 Pending JP2022525476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819870P 2019-03-18 2019-03-18
US62/819,870 2019-03-18
PCT/US2020/023250 WO2020190990A1 (en) 2019-03-18 2020-03-18 Tumor-selective combination therapy

Publications (3)

Publication Number Publication Date
JP2022525476A JP2022525476A (ja) 2022-05-16
JPWO2020190990A5 JPWO2020190990A5 (https=) 2023-03-23
JP2022525476A5 true JP2022525476A5 (https=) 2023-03-23

Family

ID=72519160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556462A Pending JP2022525476A (ja) 2019-03-18 2020-03-18 腫瘍選択的併用療法

Country Status (10)

Country Link
US (1) US20220160703A1 (https=)
EP (1) EP3942061A4 (https=)
JP (1) JP2022525476A (https=)
KR (1) KR20220004025A (https=)
CN (1) CN113905763A (https=)
AU (1) AU2020240035A1 (https=)
BR (1) BR112021018545A2 (https=)
CA (1) CA3130513A1 (https=)
MX (1) MX2021011301A (https=)
WO (1) WO2020190990A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2619331T (pt) * 2010-09-22 2018-06-01 Univ Texas Métodos de tratamento de cancro incluindo rastreio de nqo1
CA2909091C (en) * 2013-04-09 2021-11-02 The Board Of Trustees Of The University Of Illinois Tumor-selective combination therapy
WO2017025496A1 (en) * 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
SG11201808306PA (en) * 2016-03-24 2018-10-30 Tragara Pharmaceuticals Inc Treatment of cancer with tg02
KR102922386B1 (ko) * 2017-07-21 2026-02-04 제넨테크, 인크. 암에 대한 치료 및 진단 방법

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)